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Abstract
The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau
phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia
due to Alzheimer’s Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to
distinguish between AD and other types of dementia (non-AD). The concentration ratio of Aβ42 to Aβ40 (Aβ42/40 Ratio)
has been suggested to be superior to the concentration of Aβ42 alone when identifying patients with AD. This article
reviews the available evidence on the use of the CSF Aβ42/40 ratio in the diagnosis of AD. Based on the body of evidence
presented herein, it is the conclusion of the current working group that the CSF Aβ42/40 ratio, rather than the absolute
value of CSF Aβ42, should be used when analysing CSF AD biomarkers to improve the percentage of appropriately
diagnosed patients.
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Introduction
Alzheimer’s Disease (AD) is the most prevalent form of
age-related dementia. The clinical manifestation of AD is
generally preceded by a relatively symptom-free preclinical
phase [1]. After the first clinical symptoms appear in the
prodromal phase, patients transition clinically into mild
cognitive impairment (MCI) [2], which eventually results
in AD dementia (ADD) [3]. These phases are accompan-
ied by biochemical changes in the brain that are reflected
in cerebrospinal fluid (CSF) [4, 5]. Decreases in CSF con-
centrations of amyloid-beta 42 (Aβ42) (a marker of amyl-
oidosis) and elevations in tau species (markers of axonal
damage and neurofibrillary tangles) are well-established as
biomarkers useful for AD diagnosis [6, 7]. Importantly,
analysis of these CSF biochemical markers (biomarkers)
for AD has been shown to predict conversion from MCI
to ADD with accuracies of > 80% [8–10].
Depending on their age, approximately 30–50% of
patients with MCI will develop ADD within 5 years [11].
Therefore, early diagnosis is essential to enable appropri-
ate counselling to take place, as well as for planning
treatment and care. In addition, the possibility of making
an early diagnosis, prior to the appearance of symptoms,
is essential for the clinical evaluation of novel, poten-
tially disease-modifying drugs for the treatment of AD.
In an effort to improve the accuracy of an AD diagno-
sis, it is important to be able to distinguish between AD
and other types of dementia (non-AD) that are not char-
acterized by amyloid pathology. Although the concentra-
tion of another amyloid peptide species, Aβ40, has been
reported to be unaltered in AD, the concentration ratio
of Aβ42 to Aβ40 (Aβ42/40 ratio) has been suggested to be
superior to the concentration of Aβ42 alone in discrimin-
ating patients with AD [12, 13]. To date, there has been
a lack of comprehensive reviews on the applicability of
the CSF Aβ42/40 ratio in AD diagnosis.
Thus, the aim of the current article was to review the
available evidence on the use of the CSF Aβ42/40 ratio in
the (i) differential diagnosis of AD dementia vs non-AD
dementias and (ii) prediction of subsequent development
of AD dementia in cases with MCI, and to discuss its
value in comparison to other CSF biomarkers and com-
pared to other diagnostic modalities, such as Aβ positron
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emission tomography (Aβ-PET). In addition, the effects of
non-AD pathologies and pre-analytical handling on the
various CSF biomarkers were also discussed. In order to
achieve these goals, a working group was brought together
to critically evaluate the evidence for use of the CSF Aβ42/
40 ratio in the diagnosis of AD and a consensus paper was
drafted reviewing the advantages and disadvantages sur-
rounding the use of the CSF Aβ42/40 ratio.
This review addresses the advantages and disadvan-
tages of the Aβ42/40 ratio to detect Aβ pathology, which
is an approach to normalize the Aβ42 CSF concentration
for the total Aβ CSF concentration (represented by the
most abundant isoform, i.e. Aβ40). In contrast, this paper
does not address approaches to interpret the overall pat-
tern of the AD CSF biomarkers that combine results de-
rived from the two distinct AD pathologies (amyloidosis
and neurodegeneration) to form any kind of ‘ratios’.
Methods
A group of experts in the field of AD biomarkers were
brought together, and several meetings of this working
group were conducted. During the meetings, discussions
took place based both on evidence gathered from scien-
tific publications and the experience of the group mem-
bers, as experts in the field. Studies were selected to be
included in this paper based on an independent review
by at least two (in most cases by all) co-authors of the
report, with MEDLINE database as the primary source
of the studies. Searches were conducted using keywords,
such as ‘Aβ42/40’ and ‘Aβ40’ and excluding those, whose
primary scope was not the role of the Aβ42/40 ratio in
AD diagnostics. The results of the discussions and the
evidence gathered during the meetings are presented in
this paper.
Results
Aβ42 versus the Aβ42/40 ratio
Comparison of the diagnostic accuracy in the context of
use of differential diagnostics when discriminating AD from
other neurodegenerative disorders
Due to similar clinical manifestations and overlapping
brain pathologies, differentiation of AD from other neuro-
degenerative disorders may prove difficult even with the
aid of biomarkers. For example, the symptoms and bio-
marker patterns observed in patients with dementia with
Lewy bodies (DLB) or subcortical vascular dementia (VaD)
sometimes closely resemble those of AD, which makes dif-
ferential diagnosis difficult and decreases the diagnostic
accuracy of the core CSF AD biomarkers, especially in the
early stages of the disease. Therefore, evidence was gath-
ered on whether adding the CSF Aβ42/40 ratio to the exist-
ing panel of biomarkers could improve the accuracy of the
differential diagnosis of AD from other dementia disorders.
Here we provide details of 16 studies that have compared
the diagnostic accuracy of CSF biomarkers to diagnose
ADD versus non-ADDs. These studies demonstrate the
usefulness of the CSF Aβ42/40 ratio for the diagnosis of AD
in patients with dementia. Studies with relevant data are
also summarized in Table 1.
In a study of patients with ADD, normal controls, pa-
tients with non-ADD and patients with other neuro-
logical diseases, Shoji et al. [12] found that the ADD
group had a significantly higher level of tau than the
normal control group (p < 0.001), but Aβ40 levels did
not show any significant differences between the groups.
The reduction of Aβ42 levels in AD also resulted in a
significant increase in the Aβ40/42 ratio (note that the ra-
tio reported in this study has Aβ40 in the numerator, in
contrast to most of the other studies summarized in the
current paper) as an improved marker. The authors
therefore concluded that the Aβ ratio is another import-
ant marker for AD.
Lewczuk et al. [13] measured concentrations of Aβ42,
Aβ40 and total tau (T-tau) in order to compare their ac-
curacy in discriminating patients with ADD, non-ADD
and control subjects. The results showed that concentra-
tions of Aβ42 were decreased (p < 0.001) and of T-tau
were increased (p < 0.001) in ADD patients, while Aβ40
concentrations did not differ significantly among the
groups. For all groups when the Aβ42/40 ratio was used,
more patients were classified correctly, compared to
when the Aβ42 concentration alone was used (94 vs
86.7% when comparing ADD to controls, 90 vs 85%
when comparing ADD to non-ADD and 90.8 vs 87%
when comparing ADD to non-ADD plus controls). The
improvement of the diagnostic accuracy reported in this
study was not significant, probably due to the small
numbers of subjects and a clear ceiling effect (a rela-
tively high number of patients were already correctly
classified using Aβ42 alone).
Gabelle et al. [14] evaluated the value of individual and
combined measurements of CSF biomarkers. They found
that both Aβ40/42 and Aβ38/42 ratios were significantly al-
tered in AD. They also found that the Aβ40/38 ratio was the
only one that differentiated clearly control subjects from
FTD subjects, while not being significant between AD and
FTD. In the ROC curves, they found that for FTD versus
AD diagnosis, the best AUCs for amyloid biomarkers were
the Aβ38/42 ratio and the Innogenetics Aβ/Tau index (IATI)
(AUCs = 0.87). However, the Aβ40/42 ratio or Aβ42 alone
had very close and statistically undifferentiated AUC values.
The authors concluded that the Aβ38/42, Aβ40/42 and the
IATI ratios were also better than individual biomarkers to
identify AD therefore justifying their clinical relevance.
In another study carried out by Wiltfang et al. [15],
the authors found that alterations of Aβ42 concentra-
tions might not only result from AD pathology but may
also be related to total Aβ peptide concentrations. In
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Table 1 CSF biomarkers to distinguish cases with ADD from cases with non-ADD
Study Number of
AD patients
Number of
non-AD
patients
Number of
control
patients
CSF biomarkers Optimal
cut-off*
Sensitivity %
(95% CI)**
Specificity %
(95% CI)**
AUC
(95% CI)
SL
(p value)#
Shoji et al. [12] 55 68 34 Aβ42 158.6 fmol/mL – – – –
Aβ42/40 ratio## 0.078## 51 82 – NP
Lewczuk et al. [13] 22 11 35 Aβ42 550 pg/mL 100 80 0.923 –
Aβ42/40 ratio 9.75 95.2 88.4 0.944 NP
Spies et al. [22] 69 69 47 AD vs controls
16 DLB Aβ42 – 93 87 0.949 –
27 FTD Aβ42/40 ratio – 93 87 0.947 NP
26 VaD AD vs non-AD
Aβ42 – 83 74 0.811 NP
Aβ42/40 ratio – 85 85 0.903
Hertze et al. [32] 94 166 (MCI)
29 (DD)
38 AD vs controls
Aβ42 MSD < 523 73 89 0.88
(0.82–0.93)
–
Aβ42 MSD/40 ratio < 0.069 93 86 0.91
(0.86–0.95)
NP
Aβ42 MSD/38 ratio < 0.37 87 82 0.89
(0.83–0.93)
NP
MCI-AD vs MCI
Aβ42 MSD < 523 67 71 0.73
(0.66–0.80)
–
Aβ42 MSD/40 ratio < 0.069 85 71 0.86
(0.79–0.91)
NP
Aβ42 MSD/38 ratio < 0.37 88 71 0.85
(0.79–0.91)
NP
Gabelle et al. [14] 52 34 42 AD vs FTD
Aβ42 > 464 79 62 0.75 –
Aβ42/40 ratio ≤11.1 79 76 0.85 n.s.
Aβ42/38 ratio ≤2.00 88 86 0.87 n.s.
Slaets et al. [16] 80
69 (NP)
11 (AD+CVD)
75
24 DLB
(15 NP)
29 FTD
(12 NP)
22 VaD
(11 NP)
30 Aβ42 517 pg/mL 81 59 0.747
(0.670–0.827)
–
Aβ42/40 ratio 0.057 81 60 0.749
(0.673–0.826)
NP
Nutu et al. [17] 48 127
43 PD
33 PDD
51 DLB 107 AD vs control
Aβ42 444 ng/L 94 72 0.871
(0.811–0.930)
-NP
Aβ42/40 ratio 0.125 92 79 0.871
(0.801–0.933)
AD vs PDD
Aβ42 449 ng/L 94 61 0.805
(0.704–0.905)
–
Aβ42/40 ratio 0.150 90 81 0.910
(0.844–0.976)
NP
AD vs DLB
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Table 1 CSF biomarkers to distinguish cases with ADD from cases with non-ADD (Continued)
Study Number of
AD patients
Number of
non-AD
patients
Number of
control
patients
CSF biomarkers Optimal
cut-off*
Sensitivity %
(95% CI)**
Specificity %
(95% CI)**
AUC
(95% CI)
SL
(p value)#
Aβ42 387 ng/L 88 41 0.675
(0.570–0.780)
–
Aβ42/40 ratio 0.115 90 57 0.759
(0.664–0.853)
NP
Baldeiras
et al. [18]
AD vs controls
Aβ42 534 pg/mL 82 74 0.818 –
Aβ40/42 ratio 8.3 59 81 0.719 NP
AD vs FTD
Aβ42 538 pg/mL 70 82 0.791 –
Aβ40/42 ratio 5.4 59 87 0.778 NP
Dumurgier
et al. [19]
367 (AD+
non-AD)
– 0 AD vs non-AD
Aβ42 737–836
pg/mL
78 79 0.81 –
Aβ42/40 ratio 0.050–0.082 73 78 0.81 NP
Struyfs
et al. [23]
100 50 50 AD vs controls
50 (AD) 17 (DLB) Aβ42 < 722 pg/mL 98.0 74.0 0.874 –
50 (MCI-AD) 17 (FTD) Aβ42/40 ratio < 0.1099 85.7 78.0 0.881 NP
16 (VaD) Aβ42/38 ratio < 0.269 81.6 82.0 0.858 NP
AD vs non-AD
Aβ42 < 694 pg/mL 95.9 40.0 0.686 –
Aβ42/40 ratio < 0.1215 93.9 50.0 0.782 NP
Aβ42/38 ratio < 0.2730 81.6 68.0 0.804 NP
Bousiges
et al. [25]
70 55 15 Pro-AD vs pro-DLB
31 (AD-d) 20 (DLB-d) Aβ42 ≤ 730 ng/L 84.6 71.4 0.84
(0.74–0.92)
–
39 (pro-AD) 35
(pro-DLB)
Aβ42/40 ratio ≤ 0.0529 88.9 100 0.95
(0.83–0.99)
NP
AD-d vs DLB-d
Aβ42 ≤ 504 ng/L 67.7 80 0.77
(0.63–0.88)
–
Aβ42/40 ratio ≤ 0.0799 92.3 88.9 0.86
(0.64–0.97)
NP
Janelidze et al. [24] Cohort 2 Cohort 2 Cohort 2 AD vs MCI
75 (AD) 62 (MCI) 53 Aβ42 – – – 0.817
(0.743–0.890)
–
35 (MCI-AD) 34 (VaD) Cohort 3 Aβ42/40 ratio – – – 0.879
(0.823–0.936)
< 0.028
Cohort 3 47
(DLB/PDD)
328 Aβ42/38 ratio – – – 0.856
(0.790–0.923)
< 0.222
137 33 (FTD) AD vs DLB/PDD
Cohort 3 Aβ42 – – – 0.583
(0.476–0.690)
–
35
(DLB/PDD)
Aβ42/40 ratio – – – 0.792
(0.707–0.877)
< 0.001
128 (PD) Aβ42/38 ratio – – – 0.796
(0.710–0.883)
< 0.001
AD vs VaD
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such cases, healthy individuals with relatively low total
Aβ might be misdiagnosed as having ‘pathologically low’
Aβ42 concentrations, and vice versa, AD subjects with
high total Aβ might be misinterpreted as normal Aβ42
carriers. It was therefore concluded that the analysis of CSF
Aβ42 alone (i.e. without Aβ40) might lead to misinterpret-
ation of the neurochemical dementia diagnostics outcome
in subjects with constitutively high or low concentrations of
total Aβ peptides. Consequently, the authors conclude that
the CSF Aβ42/40 ratio can possibly improve the reliability of
the neurochemical dementia diagnosis.
A study by Slaets et al. [16] compared the use of dif-
ferent biomarkers for the diagnosis of AD. Addition of
the CSF Aβ42/40 ratio to the existing panel of bio-
markers, Aβ42, Aβ40 and tau phosphorylated at threo-
nine 181 (P-tau181) was compared to the panel without
the addition of the ratio. The results showed that the
CSF Aβ42/40 ratio was significantly decreased in AD pa-
tients (0.043 ± 0.021) compared to non-AD patients
(0.064 ± 0.027; p < 0.001) and controls (0.053 ± 0.023; p
< 0.001). Following receiver operating characteristic
(ROC) analysis, the optimal cut-offs discriminating the
groups were defined as the values maximising the sum
of the sensitivity and the specificity. Although the differ-
ence between the areas under the ROC curves (AUC) for
Aβ42 and Aβ42/40 turned out to be insignificant, the diag-
nostic accuracy of the decision tree that contained Aβ42,
Aβ40, P-tau181 and the Aβ42/40 ratio was significantly bet-
ter than the diagnostic accuracy of the decision tree with-
out Aβ40 and the Aβ42/40 ratio (80% vs 74%; p < 0.001).
The authors concluded that there was no difference in
CSF Aβ40 levels found between AD and non-AD patients,
but that adding CSF Aβ40 and the CSF Aβ42/40 ratio to a
biomarker-based decision tree, might have an added value
for discriminating AD from non-AD patients in cases with
intermediate CSF P-tau181 values.
Nutu et al. [17] evaluated whether the CSF Aβ42/40 ra-
tio could be used for differentiating AD from DLB and
Parkinson’s Disease Dementia (PDD). The primary find-
ing of this study was that the CSF Aβ42/40 ratio increased
Table 1 CSF biomarkers to distinguish cases with ADD from cases with non-ADD (Continued)
Study Number of
AD patients
Number of
non-AD
patients
Number of
control
patients
CSF biomarkers Optimal
cut-off*
Sensitivity %
(95% CI)**
Specificity %
(95% CI)**
AUC
(95% CI)
SL
(p value)#
Aβ42 – – – 0.698
(0.580–0.816)
–
Aβ42/40 ratio – – – 0.880
(0.814–0.946)
< 0.001
Aβ42/38 ratio – – – 0.860
(0.786–0.935)
< 0.001
AD vs non-AD
Aβ42 – – – 0.720
(0.651–0.788)
–
Aβ42/40 ratio – – – 0.863
(0.813–0.912)
< 0.001
Aβ42/38 ratio – – – 0.863
(0.813–0.913)
< 0.001
Lehmann
et al. [26]
342 562 0 AD vs non-AD
Cohort 1 Cohort 1 Cohort 1
124 276 Aβ42 500 pg/mL – – 0.78
(0.734–0.818)
–
Cohort 2 Cohort 2 Aβ42/40 ratio 0.1 – – 0.90
(0.865–0.926)
< 0.0001
218 286 Cohort 2
Aβ42 700 pg/mL – – 0.60
(0.553–0.641)
–
Aβ42/40 ratio 0.05 – – 0.77
(0.728–0.803)
< 0.0001
*Optimal cut-offs were created using different statistical approaches—please see original articles for details. **Sensitivity and specificity are a function of the cut-
off, and the cut-offs were calculated in different ways; therefore, they are not clearly comparable across different articles. #Significance levels (p values) of the AUC
values are comparisons of the Aβ isoform ratios vs Aβ42 alone.
##Note that the ratio in the original article is inversed, but for consistency, the Aβ42/40 ratio has
been calculated for this table. Aβ Amyloid beta, AD Alzheimer’s Disease, ADD AD dementia, Ad-d demented AD patients, AUC area under curve, CJD Creutzfeldt-
Jakob Disease, CSF cerebrospinal fluid, DLB dementia with Lewy bodies, DLB-d demented DLB patients, FTD frontotemporal dementia, MCI mild cognitive
impairment, MCI-AD MCI that subsequently developed ADD or MCI due to AD, NP neuropathologically confirmed, NP not provided, NPH normal pressure
hydrocephalus, n.s not significant, PD Parkinson’s Disease, PDD Parkinson’s Disease dementia, pro-AD prodromal-AD patients, pro-DLB prodromal-DLB patients, PsD
psychiatric disorders, SL significance level, VaD vascular dementia
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discrimination of AD from PDD and DLB compared
with either of the two Aβ biomarkers individually. Of
note, in this study, Aβ40 was significantly higher in AD.
Furthermore, the authors concluded that use of the
Aβ42/40 ratio could improve the differentiation of AD
from PDD and DLB.
In a study by Baldeiras et al. [18], the added value of an-
other CSF Aβ-peptide (Aβ40), along with the core CSF
markers T-tau, P-tau181 and Aβ42, in the discrimination be-
tween two large dementia groups of FTD (n = 107), AD (n
= 107) and non-demented subjects (n = 33) was evaluated.
The authors found that their data ‘taken together’ indicated
that ‘although CSF Aβ40 has no added value in the distinc-
tion between AD and FTD patients, it might be useful in
the discrimination between AD and FTD patients from
non-demented controls, and therefore could be considered
in patients diagnostic work-up’.
In a prospective study of subjects with cognitive disor-
ders at three French memory centres (Paris-North, Lille
and Montpellier; the PLM study), Dumurgier et al. [19]
assessed whether the use of the Aβ42/40 ratio would reduce
the frequency of indeterminate CSF profiles. They found
that, on the basis of local optimum cut-offs for Aβ42 and
P-tau181, 22% of patients had indeterminate CSF profiles.
The systematic use of the Aβ42/40 ratio instead of Aβ42
levels alone decreased the number of indeterminate
profiles (17%; p = 0.03), but it failed to improve the classifi-
cation of subjects (NRI = − 2.1%; p = 0.64). In contrast, use
of the Aβ42/40 ratio instead of Aβ42 levels alone in patients
with a discrepancy between P-tau181 and Aβ42 led to a re-
duction by half of the number of indeterminate profiles
(10%; p < 0.001) and was also in agreement with clinician
diagnosis (NRI = 10.5%; p = 0.003). The authors therefore
concluded that in patients with a discrepancy between CSF
P-tau181 and CSF Aβ42, the assessment of the Aβ42/40 ratio
led to a reliable biological conclusion in over 50% of cases
that agreed with a clinician’s diagnosis.
Sauvee et al. [20] investigated whether the CSF Aβ42/40
ratio could be used to improve the accuracy of diagnostic-
ally relevant conclusions in patients with ambiguous CSF
Aβ42 or tau results. They found that one third of the bio-
marker profiles of patients with atypical dementia were am-
biguous. The addition of the CSF Aβ42/40 ratio increased
the proportion of interpretable profiles from 69 to 87%,
without changing the conclusion when the usual bio-
markers (Aβ42 and P-tau181) were concordant. The authors
therefore concluded that their results support the use of
the Aβ42/40 ratio in addition to the usual CSF AD bio-
markers for patients with ambiguous profiles. They added
that this method could be specifically directed to this popu-
lation (i.e. patients with ambiguous results) in order to
improve the level of certainty for clinical routine practice.
Lewczuk et al. [21] also compared the diagnostic ac-
curacies of the CSF Aβ42/40 ratio and CSF Aβ42 alone.
Analysis of Aβ42 gave a sensitivity and specificity of
69.3% and 88.9%, respectively, whereas the Aβ42/40 ratio
showed significantly improved performance with sensi-
tivity and specificity of 93.3% and 100%, respectively.
Thus, the authors concluded that the CSF Aβ42/40 ratio
concentration shows significantly better diagnostic per-
formance compared to the CSF Aβ42 concentration
alone. It should be noted, however, that this study must
not be interpreted as providing absolute values of the
diagnostic accuracies, but their relative comparison.
In another study including various CSF biomarkers,
Spies et al. [22] investigated the CSF Aβ42/40 ratio under
the assumption that Aβ40 closely represents the total cere-
bral Aβ load. They found that the Aβ42/40 ratio improves
differentiation of AD patients from VaD, DLB and
non-ADD patients when compared to Aβ42 alone. Further-
more, they found that the Aβ42/40 ratio is a more easily in-
terpretable alternative to the combination of Aβ42, P-tau181
and T-tau when differentiating AD from either frontotem-
poral dementia (FTD) or other non-ADDs. Since they
found different Aβ40 concentrations in the various demen-
tia groups, the authors also added that it can be debated if
the Aβ42/40 ratio is a good representation of the Aβ42 frac-
tion of the total Aβ load and thus eliminates inter-individ-
ual differences in total Aβ concentrations.
A study of patients with AAD, non-ADDs (DLB, FTD,
VaD), MCI due to AD and non-demented controls found
that the CSF Aβ42/40 ratio improved the diagnostic per-
formance of Aβ42 in most differential diagnostic situa-
tions. Struyfs et al. [23] also found that the Aβ42/40 ratio
was the best biomarker to distinguish between AD-MCI
and FTD.
Similarly, Janelidze et al. [24] also found that the CSF
Aβ42/40 ratio, as well as the CSF Aβ42/38 ratio, was ‘superior
biomarkers of AD pathology compared with Aβ42 alone’.
Using three commercially available CSF biomarker immu-
noassays, this study found that the CSF Aβ42/40 and Aβ42/
38 ratios improved differentiation of AD from non-ADs,
especially when separating AD from DLB/PDD and VaD.
The authors point to several potential explanations for
the improved accuracy when using the CSF Aβ42/40 and
Aβ42/38 ratios instead of Aβ42. They suggest that it might
be that subcortical pathologies not specific to AD, such
as WMLs and alpha-synuclein pathology, cause reduced
levels of all CSF Aβ species, including Aβ42. A second
explanation for the improved diagnostic accuracy of the
Aβ42/40 and Aβ42/38 ratios could be that differences in
the overall production and clearance of Aβ probably
contribute to inter-individual variability in total CSF Aβ
levels. This is supported by the present finding that in
CSF Aβ42 correlates with Aβ38 and Aβ40 even in healthy
controls. Consequently, when detecting Aβ42 brain path-
ology with CSF Aβ42, using ratios to Aβ40 or Aβ38 might
correct for inter-individual differences in total Aβ levels.
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In another study, which evaluated the differential diag-
nosis of DLB and AD, once again, the CSF Aβ42/40 ratio
was found to aid diagnosis. The study by Bousiges et al.
[25] found that the Aβ42/40 ratio remained unchanged in
DLB patients between the prodromal and demented
stages, contrary to what was observed in AD. The Aβ42/
40 ratio therefore makes it possible to distinguish
between the two pathologies ‘at a time when the differ-
ential diagnosis is difficult’.
Finally, in a study by Lehmann et al. [26], the Aβ42/40
ratio was added to a previously described PLM scale
(Paris-Lille-Montpellier study), which combines Aβ42,
T-tau and P-tau181 biomarkers, in order to evaluate an
optimized PLMR scale (PLM ratio scale). Nine hundred
and four participants (342 AD and 562 non-AD) were
studied, in two chronologically different cohorts (400
Mtp-1 and 504 Mtp-2). For AD patients, the mean CSF
Aβ42 and CSF Aβ42/40 ratio was 553 ± 216 pg/mL and
0.069 ± 0.022 pg/mL in Mtp-1 and 702 ± 335 pg/mL and
0.045 ± 0.020 pg/mL in Mtp-2. The distribution of AD
and non-AD differed between the PLM and the PLMR
scales (p < 0.0001). The percentage AD well-classified
(class 3) increased with PLMR from 38 to 83% in Mpt-1
and from 33 to 53% in Mpt-2. A sharp reduction of the
discordant profiles going from 34 to 16.3% and from
37.5 to 19.8%, for Mtp-1 and Mtp-2 respectively, was
also observed. The authors concluded that the integra-
tion of the Aβ42/40 ratio in the PLMR scale resulted in an
easy-to-use tool which reduced the discrepancies in bio-
logically doubtful cases and increased the confidence in
the diagnosis.
In order to try to assess what is the overall impact on
diagnosis, an estimation was made of what the actual per-
centage of patients that are misdiagnosed by Aβ42 alone
and that become correctly classified with the Aβ42/40 ratio.
Assuming normal distribution of Aβ40 across the popula-
tion of interest [15], a very conservative estimation is that
neglecting Aβ40 (which is equivalent to applying Aβ42 as
the sole CSF biomarker of amyloidosis) leads to misdiag-
noses of ca. 5–10% of cases. This is further confirmed by
Baldeiras et al. [27], who found an increase in the propor-
tion of interpretable CSF profiles from 61 to 75% (i.e. ca.
20% of the baseline value) of the MCI patients. Also,
Dorey et al. [28] report that determining CSF Aβ40 con-
centrations corrected diagnosis in AD patients with
non-pathological CSF Aβ42 levels in 76.2% of cases using
the CSF Aβ42/40 ratio.
In summary, the accumulation of evidence clearly points
to the usefulness of the CSF Aβ42/40 ratio for the diagnosis
of AD in patients with dementia. The CSF Aβ42/40 ratio is
also better than CSF Aβ42 alone at distinguishing AD de-
mentia from non-AD dementias, not only from controls.
The evidence therefore strongly suggests that the CSF
Aβ42/40 ratio, rather than CSF Aβ42 alone, should be used
in the clinical work-up of AD, as a way to improve the
diagnostic accuracy for distinguishing ADD from other
dementia disorders.
Comparison of the diagnostic accuracy for predicting the
development of ADD in patients with MCI
With disease-modifying therapies on the horizon, there
is a need to be able to predict the risk of developing
ADD before the onset of dementia, i.e. during the MCI
and subjective cognitive decline (SCD) stages. The in-
creased percentage of MCI subjects with pathologic CSF
who convert to ADD, compared to those having normal
CSF, is considered a very strong argument in favour of
the use of CSF biomarkers as predictors of MCI to ADD
conversion. Here we provide details of six studies that
have compared the diagnostic accuracy of CSF bio-
markers when predicting the development of ADD in
patients with MCI. All of the studies show the added
value of the CSF Aβ42/40 ratio in accurately predicting
progression to ADD. Studies with relevant data are also
summarized in Table 2.
In a study validating the previously introduced Erlangen
Score interpretation algorithm [29], Lewczuk et al. com-
pared three- and four-biomarker-based approaches in the
German Competence Network Dementias cohort. They
found that the score based on four biomarkers (i.e. includ-
ing the Aβ42/40 ratio in addition to Aβ42) correlated better
with the ratio of pre-dementia subjects having progressed
to ADD than the score based on three biomarkers [30].
In a study by Hansson et al. [31], baseline levels of Aβ40
and Aβ42 in CSF were measured in a cohort of patients
with MCI (n = 137) in relation to the final diagnosis after
4–6 years of follow-up. The Aβ42 concentration at baseline
and the Aβ42/40 ratio were significantly decreased in MCI
patients who developed ADD compared to cognitively
stable MCI patients and MCI patients who developed
other forms of dementia (p < 0.001). The baseline levels of
Aβ40 were similar in all MCI groups but correlated with
change in Mini-Mental State Examination scores in con-
verters to ADD. The Aβ42/40 ratio was superior to Aβ42
concentration with regard to identifying incipient AD in
MCI (p < 0.05). The authors concluded that the data
provides support for the view that amyloid precursor pro-
tein metabolism is disturbed in early sporadic AD and
points to the usefulness of the Aβ42/40 ratio as a predictive
biomarker for AD.
A study by Hertze et al. [32] investigated the diagnostic
accuracy of CSF biomarkers to predict the development of
ADD within 5 years in patients with MCI. The results
showed that the predictive values of the Aβ42/40 and Aβ42/38
ratios were higher compared to that of Aβ42 alone (p < 0.01)
when using the electrochemiluminescence technology of the
Meso Scale Discovery (MSD) platform to quantify amyloid
in MCI patients. However, Aβ42 quantified with a
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bead-based multiplexing (xMAP) technology performed as
well as the MSD Aβ42/40 ratio.
A 4-year follow-up study carried out by Parnetti et al.
[33] measured CSF Aβ40, Aβ42, T-tau and P-tau181 in pa-
tients with AD, stable MCI (MCI-MCI) and MCI evolving
into ADD (MCI-AD) in order to evaluate the power of each
biomarker and/or their combination in predicting AD pro-
gression. Although they found that inclusion of the Aβ42/40
ratio instead of Aβ42 alone did not improve the prediction
power of the model in the multivariate analysis, when uni-
variate statistics were employed, they found that the Aβ42/40
ratio had an increased sensitivity with respect to Aβ42.
In a recently published paper, Baldeiras et al. [27] showed
that replacing Aβ42 by the Aβ42/40 ratio resulted in a signifi-
cant increase in the proportion of interpretable biological
profiles (from 61 to 75%, p = 0.001) of MCI patients, due to
a reduction by half in the number of suspected non-Alzhei-
mer pathophysiology cases and an increase in the propor-
tion of the high-AD-likelihood subgroup. In their study, the
risk of progression to ADD was highest in the ‘high-likeli-
hood’ group and increased when the Aβ42/40 ratio, instead
of Aβ42, combined with T-tau and P-tau181 was used for
biomarker-based categorization.
Frölich et al. [34] investigated whether the progression of
MCI to AD dementia can be predicted by cognitive, neuro-
imaging and CSF markers. They studied 115 complete
datasets from MCI patients of the ‘Dementia Competence
Network’, a German multi-centre cohort study with annual
follow-up up to 3 years. They hypothesized that since most
biomarkers reveal complementary information, a combin-
ation of biomarkers may increase the predictive power.
Their results showed that two- to four-parameter
Table 2 CSF biomarkers for predicting the development of AD in patients with MCI
Study Number of
AD patients
Number of MCI/
non-AD patients
Number of
control patients
CSF
biomarkers
Optimal
cut-off*
Sensitivity %
(95% CI)**
Specificity %
(95% CI)**
AUC
(95% CI)
SL
(p value)#
Hansson et al. [31] 0 137 (MCI) 0 Aβ42 0.64
ng/mL
93 (82–98) 53 (41–64) 0.77
(0.69–0.84)
–
Aβ42/40 ratio 0.95 87 (76–95) 78 (67–86) 0.87
(0.80–0.92)
< 0.05
Hertze et al. [32] 94 166 (MCI) 29 38 MCI-AD vs MCI
(DD) Aβ42 MSD < 523 67 71 0.73
(0.66–0.80)
–
Aβ42 MSD/40
ratio
< 0.069 85 71 0.86
(0.79–0.91)
NP
Aβ42 MSD/38
ratio
< 0.37 88 71 0.85
(0.79–0.91)
NP
Parnetti et al. [33] 28 (AD) 32 58 (MCI-MCI) 0 MCI-AD vs MCI-MCI
(MCI-AD) 28 (OND) Aβ42 420.5
pg/mL
56 (38–74) 96 (88–99) 0.85 –
Aβ42/40 ratio 5.3 71 (48–89) 92 (79–98) 0.82 NP
AD vs non-AD (OND)
Aβ42 500.0
pg/mL
63 (42–81) 79 (59–92) 0.70 –
Aβ42/40 ratio 5.0 74 (54–89) 79 (59–92) 0.78 NP
Lewczuk et al. [21] 75 (AD-
MCI)
0 45 Aβ42 691
pg/mL
69.3 88.9 0.895
(0.819–0.946)
–
Aβ42/40 ratio 0.06 93.3 100 0.970
(0.916–0.993)
< 0.0001
Baldeiras et al. [27] 168 197 (MCI) 66 Aβ42 585
pg/mL
82 83 0.882
(0.837–0.927)
–
Aβ42/40 ratio 0.068 79 86 0.874
(0.827–0.921)
n.s.
Frölich et al. [34] 0 115 (MCI) 0 Aβ42 < 600
pg/mL
74 64 0.68 –
Aβ42/40 ratio – 59 75 0.66 NP
*Optimal cut-offs were created using different statistical approaches—please see original articles for details.**Sensitivity and specificity are a function of the cut-
off, and the cut-offs were calculated in different ways, therefore they are not clearly comparable across different articles. #Significance levels (p values) of the AUC
values are comparisons of the Aβ isoform ratios vs Aβ42 alone. Aβ Amyloid beta, AD Alzheimer’s Disease, AD-MCI early AD and MCI, AUC area under curve, DD
depressive disorder, MCI mild cognitive impairment, MCI-AD mild cognitive impairment patients progressing to AD, MCI-MCI stable MCI patients, MSD Meso Scale
Discovery assay, NP not provided, n.s not significant, OND other neurological diseases, SL significance level
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combinations of the eight predictor/biomarker indices
(MMSE, CDR-sb, CERAD-DR, HCV, Aβ42, Aβ42/40, T-tau
and P-tau181) were numerically superior over the perform-
ance of a single biomarker index in predicting MCI subjects
who progressed to AD. In this dataset, however, the Aβ42/
Aβ40 ratio was not consistently superior to Aβ42 alone for
predicting AD dementia in MCI patients.
Together these reports provide evidence that clearly
demonstrates the added value of the CSF Aβ42/40 ratio in
accurately predicting progression to ADD.
In the last years, studies have also been published apply-
ing the CSF Aβ38 concentration as the reference isomer for
normalization of the Aβ42 concentration (in the form of
Aβ42/38 ratio). However, it needs to be stressed that neither
the results of these studies, nor the physiological rationale
behind using Aβ38 instead of Aβ40 is convincing enough to
replace Aβ40.
Comparison of the diagnostic accuracy of the CSF
biomarkers and Aβ-PET
CSF Aβ42 and Aβ-PET have both been found to correl-
ate highly with brain biopsy findings [35, 36]. Decreased
concentrations of CSF Aβ42 and increased retention of
amyloid tracers in the brain on PET are considered the
earliest biomarkers of AD, although some evidence sug-
gests that the alterations measurable in the CSF occur
earlier [43]. A potential advantage of Aβ-PET over CSF
Aβ42 as an early diagnostic marker is the possibility to
detect regional Aβ depositions that might occur before
the global neocortical signal becomes pathologic. On the
other hand, analysis of CSF offers a quantitative result of
the net effect of the biomarkers. Running costs of CSF
analysis are 10- to 15-fold lower than those for Aβ-PET
(total costs for lumbar puncture and analysis of four
CSF biomarkers in Germany do not exceed €200). CSF
analysis is also more accessible to patients, it does not
require the patient and caregiver to travel to a distant
centre equipped with PET facilities and it enables simul-
taneous analysis of dozens of biomarkers in one sample
volume, including biomarkers of neurodegeneration,
neuroinflammation and others [37–39]. In contrast to
neuroimaging modalities, a CSF-based approach enables
aliquoting and storage of a sample’s volume for further
analyses in the future, also in other laboratories.
Finally, although lumbar puncture is frequently regarded
as an invasive procedure, serious complications are ex-
tremely rare, with the most common, headache, only be-
ing observed in 2% of the elderly population and being
easily treated with simple analgesia [40]. On the other
hand, it is questionable to consider injection of radioactive
tracers, designed to target brain tissue, as a ‘non-invasive’
procedure. Here we provide details of five studies that
have compared the diagnostic accuracy of CSF biomarkers
and Aβ-PET, all showing that both methods can identify
early AD with high accuracy. Studies with relevant data
are also summarized in Table 3.
In Cohort 1 of a study carried out by Janelidze et al.
[24], which included 215 MCI patients, a discrepancy
between CSF Aβ42 and Aβ-PET status was observed. In
fact, they found that 10–20% of healthy individuals and
MCI patients showed a mismatch in CSF Aβ42 and
Aβ-PET status. In their study, they found that the CSF
Aβ42/40 and Aβ42/38 ratios better predict abnormal cor-
tical amyloid deposition (visualized with PET) compared
with Aβ42. The ratios increased the classification per-
formance both for patients who were falsely classified as
positive (by low CSF Aβ42) and for patients who were
falsely classified as negative (by high CSF Aβ42).
One possible explanation proposed by the authors for
the improved concordance between Aβ-PET and CSF
Aβ, when using the Aβ42/40 and Aβ42/38 ratios instead of
Aβ42, was that subcortical pathologies not specific to AD
could cause reduced levels of all CSF Aβ species, includ-
ing Aβ42, but not the ratios. For example, in patients
with MCI, low CSF Aβ42, Aβ40 and Aβ38 were all linked
to subcortical injury, including increased white matter
lesions (WML) and enlarged lateral ventricles. The
mechanisms underlying these associations are likely re-
lated to dysregulation in β amyloid precursor protein
pathways with a general decline in the production of Aβ.
A study by Lewczuk et al. [41] reported an association
between amyloid alterations reflected in the CSF with
those in Aβ-PET in a cohort of 199 patients. The results
showed that the CSF Aβ42/40 ratio corresponded better
than Aβ42 with PET results, with a larger proportion of
concordant cases (89.4% vs 74.9%, respectively, p < 0.001)
and a larger area under the ROC curve (AUC 0.936 vs
0.814, respectively, p < 0.001) associated with the ratio. For
both CSF biomarkers, the percentage of CSF-abnormal/
PET-normal cases was larger than that of CSF-normal/
PET abnormal cases. The authors concluded that the CSF
Aβ42/40 ratio is superior to Aβ42 alone as a marker of
amyloid-positivity by PET, which may be explained by the
fact that the ratio compensates for general between-indi-
vidual variations in CSF total Aβ concentrations. Further-
more, they speculated, that the fact that there was a
higher proportion of subjects with pathologic CSF (as
reflected by Aβ42 or Aβ42/40) and normal PET compared
to those with pathologic PET and normal CSF might sug-
gest that CSF reflects amyloidosis earlier than PET does.
Similar conclusions based on earlier findings in CSF com-
pared to PET were also made by Mattsson et al. and
Palmqvist et al. [42, 43].
Janelidze et al. [44] studied the concordance between
CSF Aβ42 levels measured using five different immuno-
assays [Innotest, Modified Innotest (increased antibody
concentration and incubation time, and lower CSF vol-
ume), fully automated Lumipulse, Euroimmun and MSD
Hansson et al. Alzheimer's Research & Therapy           (2019) 11:34 Page 9 of 15
Table 3 Studies comparing CSF biomarkers and Aβ-PET
Study Number of
AD patients
Number of MCI/
non-AD patients
Number of
control patients
CSF
biomarkers/ PET
Optimal
cut-off*
Sensitivity%
(95% CI)**
Specificity%
(95% CI)**
AUC
(95% CI)
SL
(p value)#
Mattsson
et al. [42]
121 68 (SCD) 161 Aβ42 < 192 ng/L – – – –
419 (MCI) Aβ42/40 ratio – – NP
Florbetapir PET > 1.11 SUV – – – NP
Janelidze
et al. [24]
Cohort 1 Cohort 1 Cohort 1 Euroimmun
0 215 (MCI) 0 Aβ42 < 507.5 pg/mL 83.2 83.3 0.894
(0.850–0.937)
–
Aβ42/40 ratio < 0.10 97.2 88.0 0.954
(0.923–0.986)
0.008
Aβ42/38 ratio < 0.29 92.5 88.9 0.943
(0.911–0.975)
0.007
MSD
Aβ42 < 495.9 pg/mL 85.0 88.9 0.916
(0.876–0.956)
–
Aβ42/40 ratio < 0.09 95.3 95.4 0.975
(0.952–0.998)
< 0.001
Aβ42/38 ratio < 0.17 97.2 91.7 0.964
(0.935–0.992)
0.007
Quanterix
Aβ42 < 1742 pg/mL 73.3 77.5 0.810
(0.707–0.913)
–
Aβ42/40 ratio < 0.16 90.0 90.0 0.912
(0.834–0.991)
0.002
Lewczuk
et al. [41]
0 199 CN & 0 Aβ42 735 pg/mL 81.6
(68.0–91.2)
72.7
(64.8–79.6)
0.814
(0.752–0.865)
–
abnormal (150
PET−/ 49 PET+)
Aβ42/40 ratio 0.05 95.9
(86.0–99.5)
88.0
(81.7–92.7)
0.936
(0.892–0.966)
< 0.001
Janelidze
et al. [44]
0 262 (MCI/SCD) 0 Innotest
Aβ42 ≤ 548 pg/mL 96 82 0.92
(0.89–0.95)
–
Aβ42/40 ratio ≤ 0.06 91 82 0.92
(0.88–0.95)
NP
Modified Innotest
Aβ42 ≤ 1091 pg/mL 92 74 0.87
(0.83–0.91)
–
Aβ42/40 ratio ≤ 0.12 92 87 0.93
(0.90–0.96)
≤ 0.01
Euroimmun
Aβ42 ≤ 449 pg/ 82 80 0.88 –
Aβ42/40 ratio mL
≤ 0.10
93 88 (0.84–0.92)
0.93
(0.90–0.96)
≤ 0.01
MSD
Aβ42 ≤ 506 pg/mL 94 76 0.89
(0.85–0.93)
–
Aβ42/40 ratio ≤ 0.08 96 89 0.95
(0.93–0.98)
≤ 0.001
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assays) and visual read of Aβ-PET images in 262 patients
with MCI or SCD. They found that although the ac-
curacy to correlate with visual 18F-flutemetamol PET
was decreased when using newer Aβ42 assays, this
limitation is overcome by using the CSF Aβ42/40 ratio.
They also found that the CSF Aβ42/40 ratio from the
newer assays showed improved accuracy for detection
of cortical Aβ fibrils as measured by PET. Moreover,
the sensitivities and specificities of these newer assays
were less influenced by moderate changes in the
cut-offs when the CSF Aβ42/40 ratio was used, a find-
ing that is important when samples will be analysed
consecutively over time.
In another study analysing the agreement between
data on cerebral amyloidosis, derived using Pittsburgh
compound B (PiB) PET and immunosorbent assay of
CSF Aβ42, Leuzy et al. [45] examined 243 subjects with
normal cognition and patients with MCI. They found
that agreement between PiB classification and MSD im-
munosorbent assay/mass spectrometry reference meas-
urement procedure findings was further improved when
using the CSF Aβ42/40 ratio.
A study by Schindler et al. [46] studied the relation-
ship between CSF biomarkers, as measured by a novel
automated immunoassay platform and Aβ-PET. They
found that CSF biomarker ratios (T-tau/Aβ42, P-tau181/
Aβ42 and Aβ42/40) best discriminated PiB-positive from
PiB-negative individuals.
These reports show that both Aβ-PET and CSF
biomarkers can identify early AD with high accuracy.
However, several studies strongly suggest that Aβ al-
terations in the CSF occur earlier [42, 43]. Similarly,
there is no convincing evidence that the spatial dis-
tribution of Aβ deposits in the brain tissue observed
in PET deliver clinically relevant information [47]. In
addition, the CSF Aβ42/40 ratio can better predict ab-
normal cortical amyloid deposition (visualized with
PET) compared with Aβ42. This then leads to fewer
patients being diagnosed as false positive (low CSF
Aβ42) or false negative (high CSF Aβ42).
Effects of non-AD pathologies on Aβ42, Aβ40 and the
Aβ42/40 ratio, such as WMLs, PDD and DLB
In clinical practice, CSF biomarker analyses are often
carried out in patients with atypical or mixed presenta-
tion of dementia. This makes the diagnosis complex and
highlights the importance of being able to discriminate
AD from other neurodegenerative processes such as
FTD, WMLs, VaD, DLB, PDD and cerebral amyloid
angiopathy [5].
Selnes et al. [48] studied the effects of cerebrovas-
cular disease on amyloid precursor protein metabo-
lites in CSF in 37 patients with SCD or MCI without
stroke, and 26 after acute stroke. They found that
CSF levels of Aβ38, Aβ40 and Aβ42 were inversely cor-
related with chronic WML volume (p ≤ 0.01; p ≤ 0.05;
p ≤ 0.05, respectively), but not with acute WML or
infarct volumes.
Similarly, van Westen et al. [49] studied the associ-
ation of cerebral WML with Aβ isoforms and Aβ-PET in
831 subjects with cognitive performance ranging from
normal to ADD. The results showed that all Aβ isoforms
were consistently inversely correlated with WML, but
the CSF Aβ42/40 ratio and Aβ-PET were not. These re-
sults indicate that the presence of WMLs affects the
levels of CSF Aβ38, Aβ40 and Aβ42, but not the CSF
Aβ42/40 ratio or Aβ-PET.
Finally, Gabelle et al. [14] observed that Aβ40
levels were decreased in FTD suggesting that it
could represent a diagnostic biomarker in this
pathology.
It can therefore be concluded that Aβ42, as well as
Aβ38 and Aβ40, might be reduced in CSF due to
non-AD related pathologies, but usually, the Aβ42/40
ratio, as well as other Aβ ratios, including Aβ42, are
not affected. These studies therefore point to the
usefulness of the CSF Aβ42/40 ratio in improving the
accuracy of the differential diagnosis in patients with
ambiguous biological profiles or with other condi-
tions that might affect the concentrations of the Aβ
peptides.
Table 3 Studies comparing CSF biomarkers and Aβ-PET (Continued)
Study Number of
AD patients
Number of MCI/
non-AD patients
Number of
control patients
CSF
biomarkers/ PET
Optimal
cut-off*
Sensitivity%
(95% CI)**
Specificity%
(95% CI)**
AUC
(95% CI)
SL
(p value)#
Schindler
et al. [46]
0 22 (MCI) 176 (CN) Aβ42 < 1.098 pg/mL – – 0.85
(0.80–0.90)
–
(~ 25% PiB+) (~ 25% PiB+) Aβ42/40 ratio < 0.075 – – 0.93
(0.89–0.96)
NP
*Optimal cut-offs were created using different statistical approaches—please see original articles for details. **Sensitivity and specificity are a function of the cut-
off, and the cut-offs were calculated in different ways, therefore they are not clearly comparable across different articles. #Significance levels (p values) of the AUC
values are comparisons of the Aβ isoform ratios vs Aβ42 alone. Aβ amyloid beta, AD Alzheimer’s Disease, ADAS-cog Alzheimer’s Disease Assessment Scale-cognitive
subscale, AUC area under curve, cen centiloid, CN cognitively normal, CU centiloid units, DLB dementia with Lewy bodies, FTD frontotemporal dementia, MCI mild
cognitive impairment, MCI-AD MCI that subsequently developed AD dementia, MSD Meso Scale Discovery, NP not provided, n.s not significant, PD Parkinson’s
Disease, PDD Parkinson’s Disease with dementia, PET, positron emission tomography, MS-RMP mass spectrometry-based candidate reference measurement
procedure, PiB carbon-11 labelled thioflavin-T derivative, Pittsburgh compound B, SCD subjective cognitive decline, SL significance level, SUV standardized uptake
value, VaD subcortical vascular dementia, vis visual
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Effects of pre-analytical handling on Aβ42 and the Aβ42/40
ratio
Various papers have pointed out pre-analytical and ana-
lytical variability between laboratories for the concentra-
tion of the Aβ42 peptide in CSF [50–54]. Tubes for
collection, sample handling and sample storage condi-
tions, in particular, have been noted as critical factors
[55, 56]. These factors have also been highlighted as a
possible reason for problems linked to inter-centre vari-
ability when it comes to analysing CSF biomarkers [57].
The type of sampling and storage tubes used is an im-
portant source of variability because of the tendency of
Aβ peptides to adsorb on plastic surfaces [21, 54, 56]. It
has been proposed that there is parallel adsorption of CSF
Aβ42 and Aβ40 onto the sampling tube surface, regardless
of the type of plastic, however with significant differences
across different type of plastics [58]. They also suggest that
systematic use of the CSF Aβ42/40 ratio would provide a
complete interpretation of CSF amyloid biomarker results,
integrating the impact of plastic tube type.
Lewczuk et al. [58] measured biomarkers of AD (T-tau,
P-tau181, Aβ42, Aβ40) in CSF samples in collection tubes
made of different materials. The results suggest that the
CSF Aβ42/40 ratio and CSF P-tau181 are much less prone
to methodologic error introduced by interactions of the
biomarkers’ molecules with the test tube surfaces com-
pared with Aβ40 and Aβ42 concentrations, similarly to the
concentrations of T-tau. The authors concluded that the
CSF Aβ42/40 ratio is a more reliable biomarker than pure
Aβ concentrations, as the Aβ42/40 ratio is less altered by
interaction with the surface of the collection tubes.
In a similar study by Gervaise-Henry et al. [59], the im-
pact of collection tubes and repetitive freeze/thaw cycles
on CSF Aβ42 and Aβ40 concentrations was investigated.
CSF from 35 patients was collected in different polypro-
pylene (PP) tubes and stored at − 80 °C. Samples were also
subjected to three successive freeze-thaw cycles. The re-
sults showed that CSF Aβ42 and Aβ40 values were signifi-
cantly different depending on the type of collection tube
and the number of freeze/thaw cycles. Although the calcu-
lation of the CSF Aβ42/40 ratio eliminated the effect of PP
tube-dependent variation, this was not the case for freeze-
thaw cycle-associated variation. The authors concluded
that the use of Aβ42/40 ratio rather than Aβ42 alone could
contribute toward pre-analytical standardization, thus
allowing for the general use of CSF AD biomarkers in rou-
tine practice.
Willemse et al. [60] tested several variables as potential
confounders influencing adsorption of Aβ peptides on the
surfaces of test tubes, including different polypropylene
tube brands, volumes, CSF Aβ42 concentrations, incuba-
tion times, pipettes, vortex intensities and other CSF pro-
teins. They found that every sample transfer from one
tube to another resulted in 5% loss of Aβ42 concentration,
which reached as high as 10% when small volumes were
used. This decrease in concentration was, however, similar
for Aβ40, resulting in stable Aβ42/40 ratios over multiple
tube transfers. Correspondingly, they conclude that use of
the Aβ42/40 ratio overcomes the effect of adsorption-de-
rived Aβ concentration loss and can therefore contribute
to increased diagnostic accuracy.
Furthermore, Vanderstichele et al. [61] determined that
using the CSF Aβ42/40 ratio mitigates many of the effects
of additional freeze/thaw cycles, tube type and CSF vol-
umes for PP storage tubes. In fact, they concluded that the
CSF Aβ42/40 ratio is clearly a more robust biomarker than
Aβ42 toward (pre-) analytical interfering factors. They also
observed that the rate of adsorption to PP recipients is
higher for Aβ42 than for the other amyloid isoforms, such
as Aβ40, and therefore using the Aβ42/40 ratio does not
completely eliminate the effects of binding of Aβ to the
tube walls of PP tubes. However, they found that ‘low
binding recipients’ are able to reduce the binding of Aβ
species to the tube walls. They concluded that integration
of the Aβ42/40 ratio and ‘low-binding tubes’ into guidance
criteria may speed up worldwide standardization of CSF
biomarker analysis.
In summary, evidence from studies on the effect of
pre-analytical handling on biomarkers of AD suggest that
use of the CSF Aβ42/40 ratio would improve the interpret-
ation of CSF amyloid biomarker results, by reducing the
impact of these factors on the final outcome. The use of
the CSF Aβ42/40 ratio could therefore contribute toward
pre-analytical standardization, allowing for the use of CSF
AD biomarkers in routine clinical practice.
Disadvantages of the use of the CSF Aβ42/40 ratio
The main disadvantage of the use of the CSF Aβ42/40 ratio
is economical and not interpretational in nature. Consid-
ering the laboratory costs of the AD biomarkers, the in-
clusion of Aβ40 increases the costs by ca. €40–50, which is
negligible when considering the total costs of the diagnos-
tic work-up and treatment of patients with suspected AD
assessed at specialized memory clinics. Furthermore, the
amount of CSF sample needed to perform this additional
test is also negligible (5–10 μL, depending on the method).
In addition, interpretation of the results when four bio-
markers (instead of three) are used is not more complex,
when a solid interpretational algorithm is validated and
consequently used.
Conclusion
There is a growing body of evidence that suggests the
better diagnostic performance of the CSF Aβ42/40 ratio
compared to CSF Aβ42 alone. In addition, it also appears
to be clear that including the CSF Aβ42/40 ratio in the
clinical workup of MCI patients improves the accuracy
of predicting progression to AD.
Hansson et al. Alzheimer's Research & Therapy           (2019) 11:34 Page 12 of 15
It has also been shown that both Aβ-PET and CSF bio-
markers can identify early amyloid pathology with high
accuracy. The CSF Aβ42/40 ratio can also better predict
abnormal cortical amyloid deposition (visualized with
PET) compared with CSF Aβ42. This then leads to fewer
patients being diagnosed as false positive (low CSF Aβ42)
or false negative (high CSF Aβ42). In addition, there is
evidence to suggest that Aβ alterations in CSF occur
earlier than they are detectable in Aβ-PET.
Addition of the CSF Aβ42/40 ratio to the usual panel of
CSF AD biomarkers for patients with ambiguous bio-
logical profiles also increases the number of interpret-
able results.
It has also been found that the use of the CSF Aβ42/40
ratio rather than CSF Aβ42 alone contributes toward
pre-analytical standardization, removing the effects of
(pre-)analytical interfering factors, such as tube type,
freeze/thaw cycles and CSF volumes.
The working group therefore makes the following
recommendations:
1. The Aβ42/40 ratio should always be analysed,
irrespective of the results of other AD biomarkers, and
without paying attention to whether Aβ42 is normal
or pathologic. This is driven by the fact that the Aβ42/
40 ratio can equally change the CSF interpretation
from ‘normal to pathologic’ as from ‘pathologic to
normal’. Analysing the Aβ42/40 ratio only in cases with
abnormal Aβ42 (leaving cases with normal Aβ42
without further consideration, i.e. as truly not having
amyloidosis) would neglect the former scenario. On
the other hand, performing Aβ42/40 ratio analysis
only in cases with normal Aβ42 (with subjects with
abnormal Aβ42 considered as truly having amyloidosis)
would neglect the latter case.
2. It should be mandatory for every laboratory to
establish their own specific reference values (cut-offs)
for the Aβ42/40 ratio and to participate in an internal
quality control programme to ensure longitudinal
stability in the measurements of Aβ42 and Aβ40, just
as it is mandatory to establish reference values and
control quality of all other biomarkers.
3. Following on from (2), it is possible to combine
laboratory results obtained on different platforms
and from different vendors. The point is only that the
reference value for the Aβ42/40 ratio must be carefully
validated. It is beyond the scope of this paper to make
suggestions on statistical methods to calculate
reference values and/or their transfer from other
laboratories or analytical platforms.
Based on the body of evidence collected here it is the
conclusion of the current working group that the CSF
Aβ42/40 ratio, rather than the absolute value of CSF
Aβ42, should be used when analysing CSF AD bio-
markers to improve the percentage of appropriately
diagnosed patients. It is also suggested that the CSF
Aβ42/40 ratio could therefore be used as a proxy for
amyloid status in AD clinical trials and eventually in
clinical care settings.
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dementia; WML: White matter lesions
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